Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)
Cybin | 6-K: Report of foreign private issuer (related to financial reporting)
Cybin | 40-F: Annual reports filed by certain Canadian issuers
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Cybin 4Q Loss C$21M >CYBN
Express News | Cybin Q4 Net Loss C$21M Vs. C$14M YoY, Cash Totaled C$209 Million As Of March 31, 2024
Express News | Cantor Fitzgerald Reiterates Overweight on Cybin
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Express News | Shares of Psychedelics Companies Are Trading Lower After an FDA Panel, on Tuesday, Rejected the Approval of MDMA Therapy for People With PTSD
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder
Cybin Spearheads Psychedelic Research Advancements
Express News | HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $5 Price Target
No Data